Lakewood-Amedex Biotherapeutics Announces First Patient Dosed In Phase 2a Trial Of Nu-3 For Infected Diabetic Foot Ulcers; Topline Data Expected In Q1 2027

Benzinga Newsdesk www.benzinga.com Positive 80.2%

Neg 0% Neu 0% Pos 80.2%

Comments

No comments yet. Be the first!